Expert Interview
A Second Look: Revolutionizing Treatment in Hematological Malignancies: Clinical Updates on Obe-cel and AUTO8 Therapies from Autolus Therapeutics
Ticker(s): AUTLInstitution: Tristar Centennial Medical Center (HCA)
- Clinical investigator at the Sarah Cannon Treansplant and Cellular Therapy Network in Nashville, TN and Clinical Director for the Adult Transplant Program.
- Manages 20 patients a year with Acute Lymphoblastic Leukemia.
- Clinical focus on therapy of hematological malignancies and the application of potentially curable cellular therapies; participates in clinical trails in transplant and cellular therapy.
Considering the pooled analysis from the FELIX Phase Ib/II and ALLCAR19 studies, can you discuss the efficacy of obe-cel in treating adult patients with r/r B-ALL, especially in terms of complete remission rates and event-free survival?
Obe-cel has shown a favorable safety profile with low rates of severe CRS and ICANS. How does this safety profile compare to traditional CD19 CAR T therapies, and what implications does it have for patient management?
The FELIX study indicated better efficacy and safety in patients with lower disease burden at lymphodepletion. Can you elaborate on the significance of leukemic burden in predicting the response to obe-cel?
With a median follow-up of over 3 years, what can you tell us about the durability of remissions and long-term safety of obe-cel in r/r B-ALL, B-NHL, and B-CLL patients?
Moving to AUTO8, the dual targeting CAR T therapy for multiple myeloma, what are the key findings from the MCARTY Phase I study regarding its efficacy, safety, and CAR T cell persistence?
How does the dual targeting approach of AUTO8 compare with single-target BCMA CAR T therapies in terms of response rates and durability in multiple myeloma treatment?
With the BLA submission for obe-cel in r/r adult B-ALL and ongoing studies for AUTO8, what future developments can we expect in the clinical application of these therapies?
Based on the data presented, how do you foresee the role of obe-cel and AUTO8 in personalized treatment strategies for hematological malignancies?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
